Former Curaleaf employee claims that in the field of cultivation in marijuana hippopotamus was ripe for forwarding the black market – and that he was fired for problems, the trial said in the federal court.
In a lawsuit filed by former director for fulfilling requirements for compliance with the requirements, Matthew Kalmik from Chicago, state regulators note numerous issues at the lytchfield cultivation facility, including potential system thefts, cut perimeter fence and inventory problems.
Cuoliph, based in Connecticut, is one of the largest companies with cannabis in the US and has 10 cannabis dispensers in Illinois and 110,000 square feet grown by a litchfield. The lawsuit has repeatedly assumed the conditions for cultivation – from the general lack of corporate supervision – were ripe for misconduct.
Read the rest of this article about the Chicago business Crane, Click here
Illinois released sales figures for several months today. The last time it published data, it was Cannabis for adults in May. The paper today explains that the reason for the missing data was the Metrc transition. “Sales tracking features in Metrc help retailers more accurately and reliably report actual sales, including all discounts and promotions at checkout. A close look at past data shows that some initial discount prices have been collected in previous months.”
Statewide adult cannabis sales rose 7.5% sequentially to $113.1 million in October, up 4.0% on the day. Annual growth was -20.5%. Here is a chart of adult sales over time:
After growing 106% in 2021, 13% in 2022 and 5% in 2023, annual sales for adults are set to grow 5.4% to $1.72 billion in 2024. So far in 2025, they have decreased by 9.9 percent.
There hasn’t been an update from the state on medical cannabis in a while. The state exempts the sale separately from its medical plan, and April issue showed that sales fell 1.6% sequentially to $19.7 million, down 13.2% year over year.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Curaleaf Reports Third Quarter 2025 Results; steady growth and stable cash generation
Q3 2025 net income: $320 million
International revenue for Q3 2025 is $46 million
Q3 2025 Adjusted Gross Profit Margin (1) 50%
Annual operating and free cash flows from continuing operations
$104 million and $57 million respectively
STAMFORD, Conn., Nov. 5, 2025 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international supplier of consumer cannabis products, today reported its financial and operating results for the third quarter ended September 30, 2025.
Curaleaf President and CEO Boris Jordan said: “We had third quarter revenue of $320 million, up 2 percent sequentially. Price compression remained the opposite, but our domestic segment remained stable and achieved modest growth. Our international segment continued its strong trajectory, delivering 12% sequential growth and 56% year-over-year growth. An increase of 115 basis points, both sequentially and year-over-year, to $69 million, representing a 22% margin, including a 200 basis point increase from our international and hemp businesses after paying down $28 million in debt. $70 million over the next two years.
Mr. Jordan continued. The “Back to Our Roots” program we initiated 12 months ago, focused on enhancing product quality, driving growth, expanding margins and optimizing cash flow, is delivering tangible results. With our domestic business poised for renewed growth while supporting rapid international expansion, I am encouraged to report that we are seeing positive momentum across the organization despite ongoing macro pressures.
Financial highlights for the third quarter of 2025
Net income was $320.2 million, down 3% year-over-year from $330.5 million in Q3 2024. Sequentially, net income increased 2% from Q2 2025 to $314.5 million
Gross profit was $159.7 million and gross profit margin was 50%, up 130 basis points year over year.
Adjusted gross profit (1) of $160.0 million and adjusted gross profit margin (1) of 50%, up 115 basis points year-over-year
Net loss attributable to Curaleaf Holdings, Inc. from continuing operations of $54.5 million, or $0.07 per share from continuing operations.
Adjusted net loss(1) from continuing operations of $48.2 million or adjusted net loss(1) per share from continuing operations of $0.06.
Adjusted EBITDA (1) of $69.3 million and Adjusted EBITDA margin ((1)) of 21.6%, down 115 basis points year over year.
New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not, however, automated. Got a secret news tip? Get in touch.
You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.
friends,
Cannabis was legalized seven years ago. Congress didn’t know exactly what it was doing at the time, but it seemed like a good thing at the time: the Farm Act of 2018. From an investor perspective, there wasn’t much excitement, although there were a few CBD-focused companies enjoying this change. These stocks did well initially, but have fallen and are all small companies that should not be publicly traded.
There have been several challenges. CBD has a good perception among consumers, and the benefits go beyond proven health problems such as treating epilepsy (Jazz Pharma, which bought GW Pharma a few years ago, sold more than $300 million of Epidiolex in Q3). Many people use CBD for many reasons, but the FDA is not involved because it is it is extremely difficult to figure out how to manage the setting about it and asked Congress for help in early 2023.
The federal government’s failure to properly regulate CBD is only part of the problem. The law was poorly written, and companies figured out ways to develop other cannabinoids, including THCA, from hemp. No one was talking about this after the Farm Act was passed, but sales of other products outside of CBD have increased due to the development of technology as well as synthetics. The hemp cannabinoid industry is booming but remains unregulated. Many states have legalized cannabis for medical use, and many have implemented adult-use programs. Unlike manufacturers and sellers of cannabis products, companies that are part of state regulated programs face a much higher level of regulation. They also face 280E taxation.
Discussed this newsletter about fourteen months ago threat and opportunity with cannabis. At the time, no major cannabis companies were involved in cannabis, but that quickly changed as the three largest MSOs all got involved. Curaleaf took one of its Florida medical cannabis dispensaries and turned it into a cannabis store. It also manufactures hemp-based products. Trulieve launched a THC beverage business, and Green Thumb Industries worked with a company that was acquired by publicly traded Agrify. Agrify became RYTHM, Inc., which is controlled by GTI. None of these companies provide much in terms of revenue or even details on the number of units sold. Canadian LPs Canopy Growth, Organigram and Tilray Brands sell THC drinks in the US
This week, another MSO, MariMed, announced it is entering the cannabis market. Glass House Brands, which established a relationship with UC Berkeley, may also enter the industry.
In that August 2024 segment, I suggested that there are good reasons for state-regulated cannabis companies to step out of their comfort zone. The hemp industry remains unregulated by the federal government, so there are potential risks that the federal government will make some changes that will make it more difficult for operators. I would like it to be properly regulated. There are too many unregulated sellers and manufacturers selling bad products to consumers. Many states are cracking down on the hemp industry as well.
One MSO, Jushi Holdings, has filed lawsuits against retailers in Pennsylvania and Virginia for failing to properly follow THC hemp laws in those states. This is not the only sign of war, as many decry the impact of hemp-based cannabinoids on the revenues of state-regulated hemp companies.
This fight is bad for carriers, but it’s also bad for consumers, in my opinion. How this plays out is very uncertain, but hopefully the federal government will be more rational about hemp products. Consumers deserve safe products that are easy to understand and that are available in restaurants and stores.
Sincerely,
Alan:
New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we published last week.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
